These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 25962435

  • 21. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T, Weisser A, Petzold A, König H, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [Abstract] [Full Text] [Related]

  • 22. [Importance of quantitative evaluation of BCR-ABL transcripts using real-time PCR for effective treatment of chronic myeloid leukemia].
    Beránek M, Voglová J, Sýkorová A, Belada D, Bláha M.
    Cas Lek Cesk; 2006 Sep; 145(1):25-9; discussion 29-30. PubMed ID: 16468238
    [Abstract] [Full Text] [Related]

  • 23. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients.
    Arun AK, Senthamizhselvi A, Mani S, Vinodhini K, Janet NB, Lakshmi KM, Abraham A, George B, Srivastava A, Srivastava VM, Mathews V, Balasubramanian P.
    Int J Lab Hematol; 2017 Jun; 39(3):235-242. PubMed ID: 28035733
    [Abstract] [Full Text] [Related]

  • 24. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
    Rostami G, Hamid M, Jalaeikhoo H.
    Gene; 2017 Sep 05; 627():202-206. PubMed ID: 28627443
    [Abstract] [Full Text] [Related]

  • 25. Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report.
    Manzella L, Tirrò E, Vitale SR, Puma A, Consoli ML, Tambè L, Pennisi MS, DI Gregorio S, Romano C, Tomarchio C, DI Raimondo F, Stagno F.
    In Vivo; 2020 Sep 05; 34(3):1481-1486. PubMed ID: 32354950
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL.
    N Engl J Med; 2006 Jun 15; 354(24):2531-41. PubMed ID: 16775234
    [Abstract] [Full Text] [Related]

  • 28. Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia.
    Arpinati M, Tolomelli G, Bochicchio MT, Castagnetti F, Amabile M, Bandini G, Bonifazi F, Stanzani M, Rosti G, Martinelli G, Baccarani M.
    Biol Blood Marrow Transplant; 2013 May 15; 19(5):735-40. PubMed ID: 23333776
    [Abstract] [Full Text] [Related]

  • 29. Breakpoint mapping of a t(9;22;12) chronic myeloid leukaemia patient with e14a3 BCR-ABL1 transcript using Nanopore sequencing.
    Zhao H, Chen Y, Shen C, Li L, Li Q, Tan K, Huang H, Hu G.
    J Gene Med; 2021 Jan 15; 23(1):e3276. PubMed ID: 32949441
    [Abstract] [Full Text] [Related]

  • 30. B-ALL Relapses After Autologous Stem Cell Transplantation Associated With a Shift from e1a2 to e14a2 BCR-ABL Transcripts: A Case Report.
    Stella S, Massimino M, Tirrò E, Vitale SR, Scalise L, Leotta S, Pennisi MS, Puma A, Romano C, Stagno F, Sapienza G, Milone G, Manzella L.
    Anticancer Res; 2019 Jan 15; 39(1):431-435. PubMed ID: 30591491
    [Abstract] [Full Text] [Related]

  • 31. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ, Ruan GR, Liu YR, Li JL, Fu JY, Wang H, Chang Y, Jiang B, Jiang Q, Jiang H, Qiu JY, Chen SS, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan 15; 26(1):1-5. PubMed ID: 15946498
    [Abstract] [Full Text] [Related]

  • 32. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
    Fava C, Rege-Cambrin G, Dogliotti I, Gottardi E, Berchialla P, Di Gioacchino B, Crasto F, Lorenzatti R, Volpengo A, Daraio F, Fantino C, Saglio G.
    Clin Lymphoma Myeloma Leuk; 2016 Aug 15; 16 Suppl():S96-S100. PubMed ID: 27131622
    [Abstract] [Full Text] [Related]

  • 33. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
    Müller MC, Gattermann N, Lahaye T, Deininger MW, Berndt A, Fruehauf S, Neubauer A, Fischer T, Hossfeld DK, Schneller F, Krause SW, Nerl C, Sayer HG, Ottmann OG, Waller C, Aulitzky W, le Coutre P, Freund M, Merx K, Paschka P, König H, Kreil S, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.
    Leukemia; 2003 Dec 15; 17(12):2392-400. PubMed ID: 14523462
    [Abstract] [Full Text] [Related]

  • 34. [Atypical BCR-ABL transcripts in patients with chronic myeloid leukemia--the scheme for the diagnosis and monitoring of minimal residual disease].
    Link-Lenczowska D, Sacha T, Zawada M, Czekalska S, Florek I, Skotnicki AB.
    Przegl Lek; 2014 Dec 15; 71(5):258-62. PubMed ID: 25248240
    [Abstract] [Full Text] [Related]

  • 35. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.
    Qin YZ, Jiang B, Jiang Q, Zhang Y, Jiang H, Li JL, Zhu HH, Li LD, Liu YR, Chen SS, Huang XJ.
    Acta Haematol; 2008 Dec 15; 120(3):146-9. PubMed ID: 19039205
    [Abstract] [Full Text] [Related]

  • 36. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y, Hardling M, Olsson B, Hezaveh R, Ricksten A, Stockelberg D, Wadenvik H.
    Ann Hematol; 2006 Dec 15; 85(12):841-7. PubMed ID: 17006667
    [Abstract] [Full Text] [Related]

  • 37. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
    Qin YZ, Li JL, Zhu HH, Ruan GR, Li LD, Zhang Y, Xu LP, Liu DH, Liu YR, Huang XJ, Chen SS, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2006 Aug 15; 27(8):511-4. PubMed ID: 17172121
    [Abstract] [Full Text] [Related]

  • 38. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M, Wei Y, Palmqvist L, Swolin B, Stockelberg D, Gustavsson B, Ekeland-Sjöberg K, Wadenvik H, Ricksten A.
    Med Oncol; 2004 Aug 15; 21(4):349-58. PubMed ID: 15579919
    [Abstract] [Full Text] [Related]

  • 39. No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.
    Pfirrmann M, Evtimova D, Saussele S, Castagnetti F, Cervantes F, Janssen J, Hoffmann VS, Gugliotta G, Hehlmann R, Hochhaus A, Hasford J, Baccarani M.
    J Cancer Res Clin Oncol; 2017 May 15; 143(5):843-850. PubMed ID: 28083711
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.